WHO WE ARE
The most effective treatment for devastating human diseases such as cancer or autoimmune disease is an innovative cell/gene therapy based upon creative idea and scrupulous understanding of human immune system.
Through close collaboration network with international partners and securement of healthcare infrastructure for systematic medical service as well as production of GMP material, BiGEN will exert its best efforts to achieve the goal of providing meaningful therapeutic benefits for patients suffering from diseases for which treatment is currently limited.
We will be pleased to see the smile of patients who have recovered their health via innovative cell/gene therapy, which definitely drives us to strive to achieve our goal.
Company Name | BiGEN Co., Ltd. |
---|---|
CEO | Mr. Myoung Ho Jeong |
Establishment | February 24, 2015 |
Capital | 10 billion KRW |
Head Office | 684, 1193, Jungang-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10414, Republic of Korea |
Pangyo Office | Telechips Bldg., #202, 27, Geumto-ro 80beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do, 13453, Republic of Korea |
Directors |
|
---|---|
Auditor | Jun Hong Min (Professor of Chung-Ang Univ.) |